{"id":364876,"date":"2025-09-01T04:32:04","date_gmt":"2025-09-01T04:32:04","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-anaptysbio\/"},"modified":"2025-09-01T04:32:04","modified_gmt":"2025-09-01T04:32:04","slug":"how-to-buy-anaptysbio","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/","title":{"rendered":"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-364876","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"AnaptysBio, Inc. (ANAB) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve bu biyoteknoloji hissesinin 2025 y\u0131l\u0131nda g\u00fc\u00e7l\u00fc klinik deneme sonu\u00e7lar\u0131 ve b\u00fcy\u00fcme potansiyeli ile neden heyecan verici yat\u0131r\u0131m f\u0131rsatlar\u0131 sundu\u011funu ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"AnaptysBio, Inc. (ANAB) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve bu biyoteknoloji hissesinin 2025 y\u0131l\u0131nda g\u00fc\u00e7l\u00fc klinik deneme sonu\u00e7lar\u0131 ve b\u00fcy\u00fcme potansiyeli ile neden heyecan verici yat\u0131r\u0131m f\u0131rsatlar\u0131 sundu\u011funu ke\u015ffedin."},"intro":"Otoimm\u00fcn tedavilerde ses getiren bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? AnaptysBio, Inc. (sembol: ANAB) ileri bilim ile ger\u00e7ek ticari potansiyeli birle\u015ftiriyor\u2014b\u00fcy\u00fcme f\u0131rsatlar\u0131 arayan yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. \u00c7\u0131\u011f\u0131r a\u00e7an klinik sonu\u00e7lar ve stratejik ortakl\u0131klarla, bu \u015firket t\u0131bb\u0131n gelece\u011fine a\u00e7\u0131lan biletiniz olabilir. Mevcut hisse performans\u0131ndan ak\u0131ll\u0131 giri\u015f stratejilerine kadar her \u015feyi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Otoimm\u00fcn tedavilerde ses getiren bir biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? AnaptysBio, Inc. (sembol: ANAB) ileri bilim ile ger\u00e7ek ticari potansiyeli birle\u015ftiriyor\u2014b\u00fcy\u00fcme f\u0131rsatlar\u0131 arayan yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. \u00c7\u0131\u011f\u0131r a\u00e7an klinik sonu\u00e7lar ve stratejik ortakl\u0131klarla, bu \u015firket t\u0131bb\u0131n gelece\u011fine a\u00e7\u0131lan biletiniz olabilir. Mevcut hisse performans\u0131ndan ak\u0131ll\u0131 giri\u015f stratejilerine kadar her \u015feyi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Kritik Tarihler<\/h2> <p>1 Eyl\u00fcl 2025 itibar\u0131yla AnaptysBio, Inc. (ANAB) NASDAQ'ta <strong>21,03 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>4 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014ANAB'\u0131n 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar fiyatlar\u0131 dramatik \u015fekilde hareket ettirmi\u015ftir.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 ANAB Hissesini Nas\u0131l Hareket Ettirir<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>6 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>20,50 $<\/td><td><strong>%8,5 Art\u0131\u015f<\/strong> (1 hafta)<\/td><\/tr> <tr><td>5 May\u0131s 2025<\/td><td>Faz 2 Verileri<\/td><td>18,75 $<\/td><td><strong>%15,2 Art\u0131\u015f<\/strong> (3 g\u00fcn)<\/td><\/tr> <tr><td>10 \u015eub 2025<\/td><td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td><td>16,20 $<\/td><td><strong>%12,8 Art\u0131\u015f<\/strong> (tahminleri a\u015ft\u0131)<\/td><\/tr> <tr><td>5 Kas 2024<\/td><td>Ortakl\u0131k Haberi<\/td><td>15,80 $<\/td><td><strong>%7,6 Art\u0131\u015f<\/strong> (yat\u0131r\u0131mc\u0131 heyecan\u0131)<\/td><\/tr> <tr><td>8 A\u011fu 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>17,40 $<\/td><td><strong>%4,3 D\u00fc\u015f\u00fc\u015f<\/strong> (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td><\/tr> <tr><td>15 May\u0131s 2024<\/td><td>Klinik Deneme Ba\u015flang\u0131c\u0131<\/td><td>14,90 $<\/td><td><strong>%3,2 Art\u0131\u015f<\/strong> (istikrarl\u0131 b\u00fcy\u00fcme)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: May\u0131s 2025 gibi olumlu klinik deneme sonu\u00e7lar\u0131 patlay\u0131c\u0131 fiyat hareketleri yarat\u0131r. Kazan\u00e7lar\u0131n beklentileri a\u015fmas\u0131 genellikle g\u00fcnler i\u00e7inde %8-15 aras\u0131 sa\u011flam kazan\u00e7lar sa\u011flar.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-Eyl\u00fcl 2025)<\/h2> <p>ANAB hisseleri <strong>\u00f6nemli volatilite<\/strong> ya\u015fad\u0131 ancak genel olarak pozitif momentum g\u00f6sterdi:<\/p> <ul> <li><strong>Mart<\/strong>: 18,20 $ (k\u0131\u015f sonras\u0131 konsolidasyon)<\/li> <li><strong>May\u0131s<\/strong>: 21,60 $ (Faz 2 romatoid artrit veri a\u00e7\u0131klamas\u0131)<\/li> <li><strong>Temmuz<\/strong>: 25,40 $ (g\u00fc\u00e7l\u00fc 2. \u00e7eyrek kazan\u00e7lar\u0131 sonras\u0131 zirve)<\/li> <li><strong>Eyl\u00fcl<\/strong>: 21,03 $ (y\u00fckseklerden mevcut geri \u00e7ekilme)<\/li> <\/ul> <p><strong>Bu ini\u015f \u00e7\u0131k\u0131\u015f neden?<\/strong><\/p> <ul> <li>Biyoteknoloji hisseleri klinik deneme haberlerine do\u011fal olarak dalgalan\u0131r<\/li> <li>2. \u00e7eyrek gelirleri 22,3 milyon $ ile iki kat\u0131ndan fazla artt\u0131 (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/06\/3128719\/0\/en\/Anaptys-Announces-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html\">2. \u00c7eyrek Finansal Sonu\u00e7lar\u0131<\/a>)<\/li> <li>\u00dclseratif kolit deneme kayd\u0131 tamamland\u0131 (<a href=\"https:\/\/www.stocktitan.net\/news\/ANAB\/anaptys-announces-second-quarter-2025-financial-results-and-provides-t9ai849p8k96.html\">\u0130\u015f G\u00fcncellemesi<\/a>)<\/li> <\/ul> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030<\/h2> <p><strong>2025 (Y\u0131l Sonu)<\/strong>: 24-28 $ (g\u00fc\u00e7l\u00fc 4. \u00e7eyrek klinik veriler bekleniyor) \u2192 <strong>AL<\/strong><br\/> <strong>2026<\/strong>: 30-35 $ (\u00fclseratif kolit onay potansiyeli)<br\/> <strong>2028<\/strong>: 45-55 $ (birden fazla \u00fcr\u00fcn hatt\u0131 ba\u015far\u0131s\u0131)<br\/> <strong>2030<\/strong>: 65+ $ (yerle\u015fik otoimm\u00fcn tedavi portf\u00f6y\u00fc)<\/p> <p><strong>Karar<\/strong>: <strong>Risk tolerans\u0131 y\u00fcksek uzun vadeli yat\u0131r\u0131mc\u0131lar<\/strong> i\u00e7in m\u00fckemmel. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar 4 Kas\u0131m sonras\u0131 kazan\u00e7 d\u00fc\u015f\u00fc\u015flerini izlemeli.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131 de\u011ferin %50\u2019den fazlas\u0131n\u0131 bir gecede silebilir<\/li> <li>Y\u00fcksek nakit t\u00fcketimi (\u00e7eyreklik 38,6M $ zarar) s\u00fcrekli finansman gerektirir<\/li> <li>Otoimm\u00fcn ila\u00e7 onaylar\u0131nda d\u00fczenleyici gecikmeler yayg\u0131nd\u0131r<\/li> <li>Daha b\u00fcy\u00fck b\u00fct\u00e7eli b\u00fcy\u00fck ila\u00e7 \u015firketleriyle rekabet<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li>Rosnilimab romatoid artritte \"hastal\u0131\u011f\u0131n en iyisi\" profilleri g\u00f6steriyor<\/li> <li>Jemperli 1 milyar $ sat\u0131\u015fa ula\u015ft\u0131\u011f\u0131nda GSK\u2019dan 75M $ kilometre ta\u015f\u0131 \u00f6demesi potansiyeli (<a href=\"https:\/\/www.tipranks.com\/news\/company-announcements\/anaptysbio-reports-q2-2025-financial-results-and-updates\">GSK Ortakl\u0131\u011f\u0131<\/a>)<\/li> <li>Faz 2 kay\u0131t tamamland\u0131, veriler 4. \u00e7eyrekte bekleniyor<\/li> <li>293,7M $ g\u00fc\u00e7l\u00fc nakit pozisyonu 2027\u2019ye kadar finansman sa\u011fl\u0131yor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %5\u2019inden fazlas\u0131n\u0131 y\u00fcksek volatiliteye sahip biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong> - Tek seferde b\u00fcy\u00fck al\u0131m yerine 100-200 $ aral\u0131klarla al\u0131m yap\u0131n<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> - Potansiyel giri\u015f noktalar\u0131 i\u00e7in 4 Kas\u0131m kazan\u00e7lar\u0131n\u0131 izleyin<\/li> <li><strong>Zamanlamay\u0131 \u00e7e\u015fitlendirin<\/strong> - Kazan\u00e7lar \u00f6ncesi yar\u0131s\u0131n\u0131, sonras\u0131 yar\u0131s\u0131n\u0131 almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <\/ol> <p>Mizahi bir bak\u0131\u015f: \"ANAB ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Koruyucu g\u00f6zl\u00fcklerinizi tak\u0131n ve deneyin tad\u0131n\u0131 \u00e7\u0131kar\u0131n!\"<\/p> <h2>\u2705 AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeli hisseleri sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"ANAB\" aramas\u0131 yap\u0131n<\/td><td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Son i\u015flem \u00f6ncesi komisyon \u00fccretlerini kontrol edin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Pocket Option, hisse senedi yat\u0131r\u0131m\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131lar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>1 dakikal\u0131k do\u011frulama<\/strong> - Herhangi bir kimlik belgesini y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme se\u00e7ene\u011fi<\/strong> - Kripto para, e-c\u00fczdanlar ve banka kartlar\u0131 dahil<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerindeki e\u011fitim kaynaklar\u0131, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 \u00f6\u011frenen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025\u2019te AnaptysBio: \u0130mm\u00fcnoloji Yenilik\u00e7isi<\/h2> <p>AnaptysBio, otoimm\u00fcn tedavi alan\u0131nda \u00e7\u0131\u011f\u0131r a\u00e7an PD-1+ T h\u00fccresi hedefleme teknolojisiyle liderdir. Romatoid artritin \u00f6tesinde, \u00fclseratif kolit ve \u00e7\u00f6lyak hastal\u0131\u011f\u0131 tedavilerini ilerletiyorlar. <strong>2025 e\u011flenceli bilgi<\/strong>: Rosnilimab tedavisi o kadar etkileyiciydi ki, hastalar ilac\u0131 b\u0131rakt\u0131ktan sonra iki ay boyunca remisyonu korudu\u2014otoimm\u00fcn tedavilerde neredeyse e\u015fi g\u00f6r\u00fclmemi\u015f bir durum!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Kritik Tarihler<\/h2>\n<p>1 Eyl\u00fcl 2025 itibar\u0131yla AnaptysBio, Inc. (ANAB) NASDAQ&#8217;ta <strong>21,03 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>4 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014ANAB&#8217;\u0131n 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar fiyatlar\u0131 dramatik \u015fekilde hareket ettirmi\u015ftir.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 ANAB Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>20,50 $<\/td>\n<td><strong>%8,5 Art\u0131\u015f<\/strong> (1 hafta)<\/td>\n<\/tr>\n<tr>\n<td>5 May\u0131s 2025<\/td>\n<td>Faz 2 Verileri<\/td>\n<td>18,75 $<\/td>\n<td><strong>%15,2 Art\u0131\u015f<\/strong> (3 g\u00fcn)<\/td>\n<\/tr>\n<tr>\n<td>10 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>16,20 $<\/td>\n<td><strong>%12,8 Art\u0131\u015f<\/strong> (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>5 Kas 2024<\/td>\n<td>Ortakl\u0131k Haberi<\/td>\n<td>15,80 $<\/td>\n<td><strong>%7,6 Art\u0131\u015f<\/strong> (yat\u0131r\u0131mc\u0131 heyecan\u0131)<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>17,40 $<\/td>\n<td><strong>%4,3 D\u00fc\u015f\u00fc\u015f<\/strong> (hedefler ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<\/tr>\n<tr>\n<td>15 May\u0131s 2024<\/td>\n<td>Klinik Deneme Ba\u015flang\u0131c\u0131<\/td>\n<td>14,90 $<\/td>\n<td><strong>%3,2 Art\u0131\u015f<\/strong> (istikrarl\u0131 b\u00fcy\u00fcme)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: May\u0131s 2025 gibi olumlu klinik deneme sonu\u00e7lar\u0131 patlay\u0131c\u0131 fiyat hareketleri yarat\u0131r. Kazan\u00e7lar\u0131n beklentileri a\u015fmas\u0131 genellikle g\u00fcnler i\u00e7inde %8-15 aras\u0131 sa\u011flam kazan\u00e7lar sa\u011flar.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-Eyl\u00fcl 2025)<\/h2>\n<p>ANAB hisseleri <strong>\u00f6nemli volatilite<\/strong> ya\u015fad\u0131 ancak genel olarak pozitif momentum g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>Mart<\/strong>: 18,20 $ (k\u0131\u015f sonras\u0131 konsolidasyon)<\/li>\n<li><strong>May\u0131s<\/strong>: 21,60 $ (Faz 2 romatoid artrit veri a\u00e7\u0131klamas\u0131)<\/li>\n<li><strong>Temmuz<\/strong>: 25,40 $ (g\u00fc\u00e7l\u00fc 2. \u00e7eyrek kazan\u00e7lar\u0131 sonras\u0131 zirve)<\/li>\n<li><strong>Eyl\u00fcl<\/strong>: 21,03 $ (y\u00fckseklerden mevcut geri \u00e7ekilme)<\/li>\n<\/ul>\n<p><strong>Bu ini\u015f \u00e7\u0131k\u0131\u015f neden?<\/strong><\/p>\n<ul>\n<li>Biyoteknoloji hisseleri klinik deneme haberlerine do\u011fal olarak dalgalan\u0131r<\/li>\n<li>2. \u00e7eyrek gelirleri 22,3 milyon $ ile iki kat\u0131ndan fazla artt\u0131 (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/08\/06\/3128719\/0\/en\/Anaptys-Announces-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html\">2. \u00c7eyrek Finansal Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li>\u00dclseratif kolit deneme kayd\u0131 tamamland\u0131 (<a href=\"https:\/\/www.stocktitan.net\/news\/ANAB\/anaptys-announces-second-quarter-2025-financial-results-and-provides-t9ai849p8k96.html\">\u0130\u015f G\u00fcncellemesi<\/a>)<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030<\/h2>\n<p><strong>2025 (Y\u0131l Sonu)<\/strong>: 24-28 $ (g\u00fc\u00e7l\u00fc 4. \u00e7eyrek klinik veriler bekleniyor) \u2192 <strong>AL<\/strong><br \/> <strong>2026<\/strong>: 30-35 $ (\u00fclseratif kolit onay potansiyeli)<br \/> <strong>2028<\/strong>: 45-55 $ (birden fazla \u00fcr\u00fcn hatt\u0131 ba\u015far\u0131s\u0131)<br \/> <strong>2030<\/strong>: 65+ $ (yerle\u015fik otoimm\u00fcn tedavi portf\u00f6y\u00fc)<\/p>\n<p><strong>Karar<\/strong>: <strong>Risk tolerans\u0131 y\u00fcksek uzun vadeli yat\u0131r\u0131mc\u0131lar<\/strong> i\u00e7in m\u00fckemmel. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar 4 Kas\u0131m sonras\u0131 kazan\u00e7 d\u00fc\u015f\u00fc\u015flerini izlemeli.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131 de\u011ferin %50\u2019den fazlas\u0131n\u0131 bir gecede silebilir<\/li>\n<li>Y\u00fcksek nakit t\u00fcketimi (\u00e7eyreklik 38,6M $ zarar) s\u00fcrekli finansman gerektirir<\/li>\n<li>Otoimm\u00fcn ila\u00e7 onaylar\u0131nda d\u00fczenleyici gecikmeler yayg\u0131nd\u0131r<\/li>\n<li>Daha b\u00fcy\u00fck b\u00fct\u00e7eli b\u00fcy\u00fck ila\u00e7 \u015firketleriyle rekabet<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li>Rosnilimab romatoid artritte &#8220;hastal\u0131\u011f\u0131n en iyisi&#8221; profilleri g\u00f6steriyor<\/li>\n<li>Jemperli 1 milyar $ sat\u0131\u015fa ula\u015ft\u0131\u011f\u0131nda GSK\u2019dan 75M $ kilometre ta\u015f\u0131 \u00f6demesi potansiyeli (<a href=\"https:\/\/www.tipranks.com\/news\/company-announcements\/anaptysbio-reports-q2-2025-financial-results-and-updates\">GSK Ortakl\u0131\u011f\u0131<\/a>)<\/li>\n<li>Faz 2 kay\u0131t tamamland\u0131, veriler 4. \u00e7eyrekte bekleniyor<\/li>\n<li>293,7M $ g\u00fc\u00e7l\u00fc nakit pozisyonu 2027\u2019ye kadar finansman sa\u011fl\u0131yor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %5\u2019inden fazlas\u0131n\u0131 y\u00fcksek volatiliteye sahip biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong> &#8211; Tek seferde b\u00fcy\u00fck al\u0131m yerine 100-200 $ aral\u0131klarla al\u0131m yap\u0131n<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> &#8211; Potansiyel giri\u015f noktalar\u0131 i\u00e7in 4 Kas\u0131m kazan\u00e7lar\u0131n\u0131 izleyin<\/li>\n<li><strong>Zamanlamay\u0131 \u00e7e\u015fitlendirin<\/strong> &#8211; Kazan\u00e7lar \u00f6ncesi yar\u0131s\u0131n\u0131, sonras\u0131 yar\u0131s\u0131n\u0131 almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<\/ol>\n<p>Mizahi bir bak\u0131\u015f: &#8220;ANAB ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. Koruyucu g\u00f6zl\u00fcklerinizi tak\u0131n ve deneyin tad\u0131n\u0131 \u00e7\u0131kar\u0131n!&#8221;<\/p>\n<h2>\u2705 AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeli hisseleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;ANAB&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Son i\u015flem \u00f6ncesi komisyon \u00fccretlerini kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Pocket Option, hisse senedi yat\u0131r\u0131m\u0131n\u0131 herkes i\u00e7in eri\u015filebilir k\u0131lar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; Stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>1 dakikal\u0131k do\u011frulama<\/strong> &#8211; Herhangi bir kimlik belgesini y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme se\u00e7ene\u011fi<\/strong> &#8211; Kripto para, e-c\u00fczdanlar ve banka kartlar\u0131 dahil<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerindeki e\u011fitim kaynaklar\u0131, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 \u00f6\u011frenen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025\u2019te AnaptysBio: \u0130mm\u00fcnoloji Yenilik\u00e7isi<\/h2>\n<p>AnaptysBio, otoimm\u00fcn tedavi alan\u0131nda \u00e7\u0131\u011f\u0131r a\u00e7an PD-1+ T h\u00fccresi hedefleme teknolojisiyle liderdir. Romatoid artritin \u00f6tesinde, \u00fclseratif kolit ve \u00e7\u00f6lyak hastal\u0131\u011f\u0131 tedavilerini ilerletiyorlar. <strong>2025 e\u011flenceli bilgi<\/strong>: Rosnilimab tedavisi o kadar etkileyiciydi ki, hastalar ilac\u0131 b\u0131rakt\u0131ktan sonra iki ay boyunca remisyonu korudu\u2014otoimm\u00fcn tedavilerde neredeyse e\u015fi g\u00f6r\u00fclmemi\u015f bir durum!<\/p>\n"},"faq":[{"question":"AnaptysBio hisseleri nereden al\u0131nabilir?","answer":"AnaptysBio hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden ANAB sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"AnaptysBio'nun klinik deneme sonu\u00e7lar\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in neden \u00f6nemli?","answer":"Klinik deneme sonu\u00e7lar\u0131 \u015firketin ila\u00e7 geli\u015ftirme ba\u015far\u0131s\u0131n\u0131 g\u00f6sterir ve genellikle hisse fiyat\u0131nda \u00f6nemli dalgalanmalara yol a\u00e7ar. Olumlu sonu\u00e7lar yat\u0131r\u0131mc\u0131 g\u00fcvenini art\u0131r\u0131r."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek nakit t\u00fcketimi, d\u00fczenleyici onay gecikmeleri ve b\u00fcy\u00fck rakiplerle rekabet gibi riskler dikkate al\u0131nmal\u0131d\u0131r."},{"question":"Yeni ba\u015flayanlar AnaptysBio hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak, dolar maliyeti ortalamas\u0131 yaparak ve fiyat uyar\u0131lar\u0131 kurarak kademeli ve dikkatli yat\u0131r\u0131m yapmak \u00f6nerilir."},{"question":"AnaptysBio'nun 2025 sonras\u0131 b\u00fcy\u00fcme potansiyeli nedir?","answer":"\u015eirketin 2025-2030 aras\u0131nda g\u00fc\u00e7l\u00fc klinik veriler, onay potansiyelleri ve geni\u015fleyen tedavi portf\u00f6y\u00fc ile \u00f6nemli b\u00fcy\u00fcme g\u00f6stermesi beklenmektedir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"AnaptysBio hisseleri nereden al\u0131nabilir?","answer":"AnaptysBio hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden ANAB sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"AnaptysBio'nun klinik deneme sonu\u00e7lar\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in neden \u00f6nemli?","answer":"Klinik deneme sonu\u00e7lar\u0131 \u015firketin ila\u00e7 geli\u015ftirme ba\u015far\u0131s\u0131n\u0131 g\u00f6sterir ve genellikle hisse fiyat\u0131nda \u00f6nemli dalgalanmalara yol a\u00e7ar. Olumlu sonu\u00e7lar yat\u0131r\u0131mc\u0131 g\u00fcvenini art\u0131r\u0131r."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek nakit t\u00fcketimi, d\u00fczenleyici onay gecikmeleri ve b\u00fcy\u00fck rakiplerle rekabet gibi riskler dikkate al\u0131nmal\u0131d\u0131r."},{"question":"Yeni ba\u015flayanlar AnaptysBio hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak, dolar maliyeti ortalamas\u0131 yaparak ve fiyat uyar\u0131lar\u0131 kurarak kademeli ve dikkatli yat\u0131r\u0131m yapmak \u00f6nerilir."},{"question":"AnaptysBio'nun 2025 sonras\u0131 b\u00fcy\u00fcme potansiyeli nedir?","answer":"\u015eirketin 2025-2030 aras\u0131nda g\u00fc\u00e7l\u00fc klinik veriler, onay potansiyelleri ve geni\u015fleyen tedavi portf\u00f6y\u00fc ile \u00f6nemli b\u00fcy\u00fcme g\u00f6stermesi beklenmektedir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T04:32:04+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-09-01T04:32:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/\",\"name\":\"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-09-01T04:32:04+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/","og_locale":"tr_TR","og_type":"article","og_title":"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/","og_site_name":"Pocket Option blog","article_published_time":"2025-09-01T04:32:04+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-09-01T04:32:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/","name":"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-09-01T04:32:04+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-anaptysbio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"AnaptysBio, Inc. (ANAB) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; AnaptysBio, Inc. (ANAB) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":364874,"slug":"how-to-buy-anaptysbio","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu AnaptysBio, Inc. (ANAB) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu AnaptysBio, Inc. (ANAB)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-anaptysbio\/"},"pt_AA":{"locale":"pt_AA","id":364877,"slug":"how-to-buy-anaptysbio","post_title":"Como comprar a\u00e7\u00f5es da AnaptysBio, Inc. (ANAB) - Investimento em a\u00e7\u00f5es da AnaptysBio, Inc. (ANAB)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-anaptysbio\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/364876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=364876"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/364876\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=364876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=364876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=364876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}